A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Trial Profile

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs TVB 2640 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors 3-V Biosciences
  • Most Recent Events

    • 11 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 31 Mar 2017 According to a 3-V Biosciences media release, the company will present data from this trial at the AACR annual meeting in Washington, D.C.
    • 13 Mar 2017 Planned number of patients changed from 131 to 180.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top